Modern management tactics for patients with polycysticovary syndrome and obesity

The purpose of this study is to evaluate the effectiveness of complex therapy, including correction of eating behavior, a reduction diet, taking didrogesterone from the 14th to the 25th day of the cycle, 100 mg 2 times a day, as well as taking a complex drug containing myo- and D- chiroinositol in a ratio of 5:1, manganese and folic acid (myoinositol 1000 mg, D-chiroinositol 200 mg, manganese 5 mg, folic acid 200 mcg) 1 sachet 2 times a day in the management of patients with polycystic ovary syndrome (PCOS) and obesity. The object of our study was 28 women of reproductive age with PCOS. All patients underwent a comprehensive clinical and laboratory examination in accordance with the clinical recommendations of Polycystic Ovary syndrome. The content of total cholesterol and high and low density lipoproteins, triglycerides, as well as fasting and post-carbohydrate glucose levels were assessed. The patients showed clinical signs of hyperandrogenism, and there was a visceral type of obesity (CW/CH 0.85±0.01 cm). Impaired glucose tolerance was detected. We prescribed therapy for the patients, taking into account the revealed changes in hormonal balance and insulin resistance. At the first stage of complex therapy, patients were prescribed dietary behavior correction, a reduction diet, didrogesterone from the 14th to the 25th day of the cycle, 100 mg 2 times a day, as well as taking a complex remedy containing myo- and D-chiroinositol in a ratio of 5:1, manganese and folic acid (myoinositol 1000 mg, D-chiroinositol 200 mg, manganese 5 mg, folic acid 200 mcg, dietary supplement, produced by PIZETAPHARMA, S.p.A., Italy), for 3 months, 1 sachet 2 times a day. No adverse reactions were detected during this treatment. As a result of treatment, 18 out of 28 patients had a decrease in BMI to 26.6, and 11 to 25.5, respectively. Comprehensive treatment was continued for the patients. After 3 months, BMI values were re-determined. In 18 (60%) patients, they were 25.5 and in 11-24.5. Normalization of glucose tolerance was noted in all the examined patients after 6 months. 5 patients became pregnant without the use of additional ovulation-stimulating drugs. All the treated patients noted an improvement in their general well-being and quality of life.

Obesity, polycystic ovary syndrome, menstrual disorders, insulin resistance

1. Smetnik V.P., Tumilovich L.G. Nonoperative gynecology. Moscow: Medical Information Agency, 2006. 632 p. (In Russ.)@@ Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. Москва: Медицинское информационное агентство, 2006. 632 с.

2. Vorontsova A.V., Gasparyan S.A., Gromova O.A. et al. The conclusion of the Expert Council ‘The product rationale based on inositol for use by patients with menstrual irregularities’.Russian Journal of Human Reproduction. 2020;26(1):44-54. (In Russ.) doi: 10.17116/repro20202601144.@@ Воронцова А.В., Гаспарян С.А., Громова О.А. и соавт. Заключение совещания экспертов «Обоснование применения средств на основе инозитола у пациенток с нарушениями менструального цикла» Проблемы репродукции. 2020;26(1): 44-54. doi: 10.17116/repro20202601144.

3. Gerli S., Papaleo E., Ferrari A., Di Renzo G.C. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347-54. Retraction in: Eur Rev Med Pharmacol Sci. 2023 Sep;27(18):8323. doi: 10.26355/eurrev_202309_33752.

4. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006 Oct 12;443(7112):651-7. doi: 10.1038/nature05185.

5. Larner J., Huang L.C., Schwartz C.F. et al. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol. BiochemBiophys Res Commun. 1988 Mar 30;151(3):1416-26. doi: 10.1016/s0006-291x (88)80520-5.

6. Lauretta R., Lanzolla G., Vici P. et al. Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk.Int J Endocrinol. 2016; 2016:8671762. doi: 10.1155/2016/8671762.

7. Croze M.L., Soulage C.O. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct;95(10):1811-27. doi: 10.1016/j.biochi.2013.05.011.

8. Sun T.H., Heimark D.B., Nguygen T. et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. BiochemBiophys Res Commun. 2002 May 10;293(3):1092-8. doi: 10.1016/S0006-291X (02)00313-3.

9. Yap A., Nishiumi S., Yoshida K., Ashida H. Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives. Cytotechnology. 2007 Dec;55(2-3):103-8. doi: 10.1007/s10616-007-9107-y.

10. Dang N.T., Mukai R., Yoshida K., Ashida H. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. BiosciBiotechnolBiochem. 2010;74(5):1062-7. doi: 10.1271/bbb.90963.

11. Gromova J.A., Torshin I. Yu., Limanova O.A. Perspectives of using myo-inositol in women with polycystic ovary syndrome and insulin resistance as a part of pregravid preparation for in vitro fertilization. Effective pharmacotherapy. Obstetrics and Gynecology. 2013; 51(5): 12: 23. (In Russ.)@@ Громова О.А., Торшин И.Ю., Лиманова О.А. Перспективы использования мио-инозитола у женщин с поликистозом яичников и инсулинорезистентностью в программах прегравидарной подготовки к экстракорпоральному оплодотворению. Эффективная фармакотерапия. Акушерство и гинекология. 2013;51(5):12-23.

12. Gulyaev A.E., Nurgozhin T.S., Yermekbayeva B.A. et al. Metformin as a promising geroprotector (literature review).Russkii meditsinskii zhurnal. 2011;19(31):1986-1989. (In Russ.)@@ Гуляев А.Е., Нургожин Т.С., Ермекбаева Б.А. и соавт. Метформин как перспективный геропротектор (обзор литературы). Русский медицинский журнал. 2011;19(31):1986-1989.

13. Polycystic ovary syndrome. Clinical guidelines: (E28.2): developed by clin. Recommendations of the Russian Society of Obstetricians and Gynecologists, the Russian Association of Endocrinologists: year of approval 2024 (revision every 3 years): age group adults, children. - Text: electronic // Russian Society of Obstetricians and Gynecologists. - Section of the website “Clinical recommendations - projects”: [website] (In Russ.). Available at: https://roag-portal.ru/projects_gynecology (date of access: 31.12.2024).@@ Синдром поликистозных яичников. Клинические рекомендации: (Е28.2): разработчик клин. рекомендаций Российское общество акушеров-гинекологов, Российская ассоциация эндокринологов: год утверждения 2024 (пересмотр каждые 3 года): возрастная категория взрослые, дети. - Текст: электронный // Российское общество акушеров-гинекологов. - Раздел сайта «Клинические рекомендации - проекты»: [сайт]. Доступ: https://roag-portal.ru/projects_gynecology (дата обращения: 31.12.2024)